<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04162470</url>
  </required_header>
  <id_info>
    <org_study_id>R3918-PNH-1868</org_study_id>
    <secondary_id>2019-000130-20</secondary_id>
    <nct_id>NCT04162470</nct_id>
  </id_info>
  <brief_title>REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.</brief_title>
  <official_title>An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the long-term safety, tolerability, and&#xD;
      effect on intravascular hemolysis of REGN3918 in patients with paroxysmal nocturnal&#xD;
      hemoglobinuria (PNH).&#xD;
&#xD;
      The secondary objectives of the study are:&#xD;
&#xD;
        -  To evaluate the long-term effect of REGN3918 on intravascular hemolysis&#xD;
&#xD;
        -  To assess the concentrations of total REGN3918 in serum&#xD;
&#xD;
        -  To evaluate the occurrence of the immunogenicity of REGN3918&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 3, 2019</start_date>
  <completion_date type="Anticipated">December 13, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 13, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to week 104</time_frame>
    <description>TEAEs include adverse events (AEs), serious adverse events (SAEs), AEs of special interest (AESIs), laboratory data, vital signs, and electrocardiograms (ECGs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients achieving lactate dehydrogenase (LDH) less than or equal to 1.5ULN</measure>
    <time_frame>Up to week 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with breakthrough hemolysis</measure>
    <time_frame>Up to week 26, 78, 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate/number of units of transfusion</measure>
    <time_frame>Up to week 26, 78, 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of patients who are transfusion-free (with red blood cell [RBCs])</measure>
    <time_frame>Up to week 26, 78, 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of patients achieving adequate control of their intravascular hemolysis</measure>
    <time_frame>Up to week 78, 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of patients achieving normalization of their intravascular hemolysis</measure>
    <time_frame>Up to week 26, 78, 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in LDH from baseline of the Open-label extension (OLE) study</measure>
    <time_frame>Up to week 26, 78, 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent changes in LDH from baseline of the OLE study</measure>
    <time_frame>Up to week 26, 78, 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in RBC hemoglobin levels from baseline of the OLE study</measure>
    <time_frame>Up to week 26, 78, 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in free hemoglobin levels from baseline of the OLE study</measure>
    <time_frame>Up to week 26, 78, 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of REGN3918 in serum</measure>
    <time_frame>Up to week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent anti-drug antibodies (ADA) to REGN3918</measure>
    <time_frame>Up to week 104</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria</condition>
  <arm_group>
    <arm_group_label>REGN3918</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have completed 1 of the 2 parent studies (R3918-PNH-1852 [NCT03946748] or R3918-PNH-1853)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN3918</intervention_name>
    <description>Subcutaneous (SC) every week (QW) over the treatment period</description>
    <arm_group_label>REGN3918</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        â€¢ Patients with PNH who have completed, without discontinuation, study treatment in one of&#xD;
        the parent studies in which they participated (either R3918-PNH-1852 [NCT03946748] or&#xD;
        R3918-PNH-1853)&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Significant protocol deviation(s) in the parent study based on the investigator's&#xD;
             judgment and to the extent that these would (if continued) impact the study objectives&#xD;
             and/or safety of the patient (for example, repetitive non-compliance with dosing by&#xD;
             the patient)&#xD;
&#xD;
          -  Any new condition or worsening of an existing condition which, in the opinion of the&#xD;
             investigator, would make the patient unsuitable for enrollment or could interfere with&#xD;
             the patient participating in or completing the study&#xD;
&#xD;
        NOTE: Other protocol defined exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Sha Tin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Budapest</city>
        <zip>1907</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Seoul</city>
        <zip>07985</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Miri</city>
        <state>Sarawak</state>
        <zip>98000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Sibu</city>
        <state>Sarawak</state>
        <zip>96000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Kuala Terengganu</city>
        <state>Terengganu</state>
        <zip>20400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Taipei City</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS97TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PNH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

